Related Experiment Video
Updated: Apr 21, 2026

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
Statins for the prevention of contrast-induced acute kidney injury
Timothy Ball1, Peter A McCullough
1Baylor University Medical Center, Baylor Heart and Vascular Institute, Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, Tex., USA.
Insights
Short-term statin use, specifically rosuvastatin, can prevent contrast-induced acute kidney injury (CI-AKI) in high-risk patients undergoing cardiovascular procedures. This intervention is beneficial before contrast administration in patients with acute coronary syndrome and diabetes mellitus.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Acute kidney injury (AKI) is a frequent complication, particularly after cardiovascular procedures, often worsened by iodinated contrast agents.
- Contrast-induced AKI (CI-AKI) elevates risks for myocardial infarction, stroke, heart failure, CKD progression, ESRD, and mortality.
- Statins have shown benefits in chronic kidney disease (CKD) by reducing albuminuria but not glomerular filtration rate decline.
Purpose of the Study:
- To evaluate the efficacy of short-term statin administration in preventing CI-AKI.
- To assess the role of rosuvastatin in high-risk patients undergoing procedures requiring iodinated contrast.
Main Methods:
- Meta-analyses indicated a protective effect of short-term statin use against CI-AKI.
- Two large randomized controlled trials investigated rosuvastatin for CI-AKI prevention in acute coronary syndrome and diabetes mellitus patients.
- Rosuvastatin was administered prior to contrast exposure in statin-naive individuals.
Main Results:
- Both randomized controlled trials demonstrated a significant benefit of rosuvastatin in preventing CI-AKI.
- The positive findings were observed in high-risk patient populations undergoing coronary angiography.
Conclusions:
- Short-term statin therapy, particularly rosuvastatin, is supported for preventing CI-AKI in patients undergoing contrast-enhanced cardiovascular procedures.
- This strategy is recommended for statin-naive patients with acute coronary syndrome and diabetes mellitus undergoing coronary angiography.
Abstract:
Acute kidney injury (AKI) is a common medical problem, especially in patients undergoing cardiovascular procedures. The risk of kidney damage has multiple determinants and is often related to or exacerbated by intravenous or intra-arterial iodinated contrast. Contrast-induced AKI (CI-AKI) has been associated with an increased risk of subsequent myocardial infarction, stroke, the development of heart failure, rehospitalization, progression of chronic kidney disease, end-stage renal disease, and death. Statins have been studied extensively in the setting of chronic kidney disease and they have been shown to reduce albuminuria, but they have had no effect on the progressive reduction of glomerular filtration or the need for renal replacement therapy. Several meta-analyses have shown a protective effect of short-term statin administration on CI-AKI and led to two large randomized controlled trials evaluating the role of rosuvastatin in the prevention of CI-AKI in high-risk patients with acute coronary syndrome and diabetes mellitus. Both trials showed a benefit of rosuvastatin prior to contrast administration in a statin-naive patient population. In aggregate, these studies support the short-term use of statins specifically for the prevention of CI-AKI in patients undergoing coronary angiography with or without percutaneous coronary intervention.
More Related Videos
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Acute Kidney Injury I: Introduction
Cardiac Catheterization I: Pre-Procedure Overview
Imaging Studies VII: Vascular Imaging

